The DOI matches its Crossref record.
Treatment Practices, Outcomes, and Costs of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, United States, 2005–2007
Open accessAbstract
To describe factors associated with multidrug-resistant (MDR), including extensively-drug-resistant (XDR), tuberculosis (TB) in the United States, we abstracted inpatient, laboratory, and public health clinic records of a sample of MDR TB patients reported to the Centers for Disease Control and Prevention from California, New York City, and Texas during 2005-2007.At initial diagnosis, MDR TB was detected in 94% of 130 MDR TB patients and XDR TB in 80% of 5 XDR TB patients.Mutually exclusive resistance was 4% XDR, 17% pre-XDR, 24% total first-line resistance, 43% isoniazid/rifampin/rifabutin-plus-other resistance, and 13% isoniazid/rifampin/rifabutin-only resistance.Nearly three-quarters of patients were hospitalized, 78% completed treatment, and 9% died during treatment.Direct costs, mostly covered by the public sector, averaged $134,000 per MDR TB and $430,000 per XDR TB patient; in comparison, estimated cost per non-MDR TB patient is $17,000.Drug resistance was extensive, care was complex, treatment completion rates were high, and treatment was expensive. D rug-resistant Mycobacterium tuberculosis poses sub-stantial obstacles to tuberculosis (TB) control.In the United States, multidrug-resistant (MDR) TB (resistant to at least isoniazid and rifampin) comprises only 1.0%-1.5% of TB cases but requires lengthy regimens of toxic drugs, imposes high costs on the health care system and society, and causes high mortality rates.Studies of MDR TB in the United States have been limited by small sample sizes, limited study periods, minimal information on outcomes and costs, or reliance solely on surveillance data (1-6), which omit some cases of acquired drug resistance and changes in regimens.Costs of treating MDR TB are not routinely collected or reported.Our study describes and analyzes characteristics associated with drug resistance, timely diagnosis, treatment practices, outcomes, and costs associated with MDR TB for cases reported to the Centers for Disease Control and Prevention (CDC) by California, New York, and Texas during 2005-2007.These 3 areas contribute about half of US MDR TB cases annually. MethodsCDC and local institutional review boards approved the study and granted a waiver of patient informed consent and patient authorization.We defined a 5-drug regimen (online Technical Appendix, wwwnc.cdc.gov/EID/article/20/5/13-1037-Techapp1.pdf) to be consistent with US and World Health Organization recommendations (7,8).All study definitions are in the online Technical Appendix.Each site identified cases of MDR TB and extensively drug-resistant (XDR) TB reported to CDC during Treatment Practices, Outcomes, and Costs of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, United States, 2005
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Multidrug Resistance: An Emerging Crisis
Tanwar, J., Das, S., Fatima, Z., & Hameed, S. (2014) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2014/541340 · Cited by 657
Ahmad, N., Ahuja, S. D., Akkerman, O. W., Alffenaar, J.-W. C., Anderson, L. F., Baghaei, P., Bang, D., Barry, P. M., Bastos, M. L., Behera, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31644-1 · Cited by 632
Self-citationTreatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., Daley, C. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1874st · Cited by 462
Self-citationThe status of tuberculosis vaccine development
Schrager, L. K., Vekemens, J., Drager, N., Lewinsohn, D. M., & Olesen, O. F. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30625-5 · Cited by 196
Laryngeal tuberculosis: A forgotten disease
Matsuura, H., & Yamaji, Y. (2017) · QJM: An International Journal of Medicine · doi:10.1093/qjmed/hcx078 · Cited by 7
Metadata
- Authors
- Marks, S. M., Flood, J., Seaworth, B., Hirsch-Moverman, Y., Armstrong, L., Mase, S., Salcedo, K., Oh, P., Graviss, E. A., Colson, P. W., Armitige, L., Revuelta, M., Sheeran, K., & the TB Epidemiologic Studies Consortium
- Venue
- Emerging Infectious Diseases
- Published
- 2014-05
- Volume
- 20
- Issue
- 5
- Pages
- 812-821
- ISSN
- 1080-6040 (ISSN-L)
- 1080-6059
- OpenAlex
- W2146172570
- Cited by
- 179
- References
- 0
- FWCI
- 13.20
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.